Back to results
US 2025/0144168 A1Published application
Lanthipeptides and methods of use
AssigneeOstia Sciences Inc.
InventorsAbdelahhad Barbour, Michael Glogauer
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOstia Sciences Inc.
InventorsAbdelahhad Barbour, Michael Glogauer
Estimating the term…
Compositions comprising a pre-SrnA1 peptide, an SrnA1 peptide, a pre-SrnA2 peptide, an SrnA2 peptide, a pre-SrnA4 peptide, a SrnA4, and other peptides and post-translationally modified versions thereof are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.
A composition comprising a pre-SrnA1 peptide having a sequence of SEQ ID NO.:
2-4. (canceled)
The composition of claim 4 wherein the post translational modifications comprise a single phosphorylation at Thr4 amino acid of each or all of SrnA1, SrnA2 and SrnA4.
(canceled)
10-11. (canceled)
The composition of claim 11 wherein the SALI-10 comprises an SrnM lanthionine synthetase having a sequence of SEQ ID NO:9.
(canceled)
22-29. (canceled)
Method of modulating an anti-inflammatory response, modulating phagocytic activity of neutrophils, or activating reactive oxygen species of neutrophils in a patient in need thereof, comprising administering a pharmaceutically acceptable amount of salivaricin peptides to the patient.
31-32. (canceled)
34-35. (canceled)
An isolated S. salivarius strain SALI-10 having:
37-40. (canceled)
45-46. (canceled)
Dependencies are inferred from the claim text.